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Abstract
Background: Our objective was to investigate luteinizing hormone, follicle-stimulating hormone, testosterone,
and androstenedione as predicitve markers for ovulation after laparoscopic ovarian drilling.
Methods: We retrospectively analyzed 100 clompihen-resistant patients with the polycystic ovary syndrome
who underwent laparoscopic ovarian drilling at our department. The main outcome measure was spontaneous
postoperative ovulation within three months after laparoscopic ovarian drilling. In order to predict spontaneous
ovulation, we tested the following parameters by use of a univariate followed by a multivariate regression model:
Preoperative serum levels of LH, FSH, testosterone, and androstenedione as well as patients' age and body mass
index. In addition, we focused on pregnancy and life birth rates.
Results: Spontaneous ovulation was documented in 71/100 patients (71.0%). In a univariate and multivariate
analysis, luteinizing hormone (OR 1.58, 95%CI: 1.30-1.92) and androstenedione (OR 3.03, 95%CI: 1.20-7.67), but
not follicle-stimulating hormone and testosterone were independent predictors of ovulation. Using a cut-off for
luteinizing hormone and androstenedione of 12.1 IU/l and 3.26 ng/ml, respectively, spontaneous ovulation was
observed in 63/70 (90.0%) and 36/42 patients (85.7%) with elevated and in 8/30 (26.7%) and 35/58 (60.3%) patients
with low luteinizing hormone and androstenedione levels, respectively. The sensitivity, specificity, positive and
negatvie predictive values for luteinizing hormone and androstendione as predictors of spontaneous ovulation
after ovarian drilling were 88.7% (95%CI: 79.0-95.0%), 75.9% (95%CI: 56.5-89.7%), 90.0% (95%CI: 80.5-95.8%),
and 73.3% (95%CI: 54.1-87.7%) for luteinizing hormone, and 50.7% (95%CI: 38.6-62.8%), 79.3% (95%CI: 60.3-
92.0%), 85.7% (95%CI: 71.5-94.6%), and 39.7% (95%CI: 27.0-53.4%) for androstenedione, respectively. Complete
one-year follow-up was available for 74/100 patients (74%). We observed a one-year pregnancy rate and a
resulting life-birth rate of 61% and 51%, respectively.
Conclusions: Luteinizing hormone and androstenedione prior to laparoscopic ovarian drilling are independent
predictors of spontaneous ovulation within three months of surgery. We suggest to preferentially performing
laparoscopic ovarian drilling in patients with high luteinizing hormone and androstenedione levels.
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Polycystic ovary syndrome (PCOS) is the most common
female endocrinopathy with an incidence of 5-10% in the
female population. It is characterized by an overproduc-
tion of ovarian androgens thereby leading to symptoms
such as anovulation, oligomenorrhea, hirsutism, acne,
and infertility [1]. Laparoscopic ovarian drilling (LOD) is
a treatment option for clomiphene citrate-resistant infer-
tile women with PCOS. It has been reported that LOD
leads to induction of spontaneous ovulation in 30-90% of
women undergoing this procedure [2].
In a prospective randomized controlled trial comparing
LOD to gonadotropin treatment for clomiphene citrate-
resistant infertile women, Farquhar et al. reported no sig-
nificant differences in pregnancy and miscarriage rates [3].
LOD is accompanied by lower direct and indirect costs
and a reduction in multiple pregnancies compared to
gonadotropins [4]. Therefore, LOD is a reasonable alter-
native to gonadotropin stimulation in clomiphene citrate-
resistant infertility patients.
Up to 70% of women with PCOS respond to LOD [5]. In
order to optimize the efficacy of therapeutic regimens it
would be helpful to reliably predict a successful response
to LOD in order to better counsel patients about this treat-
ment option. Previous studies, published by Abdel et al.
[6] and by Li et al. [7], demonstrated that patients with
elevated preoperative luteinizing hormone (LH) levels
had a better response to LOD compared to patients with
low LH levels (> 12 IU/l and > 10 IU/l, respectively). A
recent retrospective study of Hayashi et al. [8] also indi-
cated that preoperative serum luteinizing hormone (LH)
levels are a good predictor of LOD efficacy. Significantly
higher preoperative LH levels were found in women who
ovulated after LOD compared to those who did not ovu-
late. In a multiple logistic regression model, neither testo-
sterone, nor follicle simulating hormone (FSH) or the LH/
FSH ratio were associated with the likelihood of ovulation
after LOD [8].
The aim of our study was to investigate LH, FSH, testoster-
one and androstenedione as predictive markers for thera-
peutic success of LOD, defined as spontaneous ovulation
within three months after LOD.
Methods
Patient collective
In a retrospective cohort study all clomiphene citrate-
resistant women with PCOS who underwent LOD at the
Department of Gynecology and Obstetrics of the Medical
University of Vienna, Vienna, Austria, between January
2001 and December 2008 were included. PCOS was diag-
nosed according to the revised European Society of
Human Reproduction and Embryology (ESHRE) and
American Society for Reproductive Medicine (ASRM) cri-
teria of 2004 which were based on the Rotterdam criteria
[9]. Clomiphene citrate resistance was defined as the
absence of developing follicles after ovarian stimulation
with 150 mg clomiphene citrate/day given for 5 days
beginning with the 2nd day of the menstrual cycle. Patients
were stimulated with clomiphene for a minimum of three
and a maximum of six cycles. A total of 121 patients who
met these criteria and underwent LOD were identified, of
whom 21 patients were lost to follow-up. All patients had
been pretreated with metformin for at least three months.
For details on characteristics of the remaining 100
patients see Table 1.
Study design
The primary objective of the study was to assess independ-
ent predictors of the therapeutic success of LOD, namely
spontaneous ovulation within 3 months after LOD. As a
secondary objective, we evaluated the pregnancy rate
within one year after LOD and the resulting life birth rate.
In the course of this retrospective study, we focused on the
preoperative serum levels of LH, FSH, testosterone, and
androstenedione as candidates for predicting the success
of LOD. These parameters are known to be altered in
PCOS patients and thus might be useful for the prediction
of spontaneous ovulation. Also, we included the patient's
age and body mass index (BMI) in the univariate analysis,
since these have previously been shown to be associated
with LOD outcome [7,10]. Also, we included the type of
surgical technique in the univariate analysis in order to
demonstrate that this variable has no influence on the
response to LOD. In addition, we evaluated the postoper-
ative LH and androstenedione levels.
Preoperative assessment of hormonal parameters was
done within three months before LOD. The clinical end-
point was the identification of at least one spontaneous
ovulation within three months after LOD. Ovulation was
defined as elevation of the serum progesterone level >8.0
ng/ml according to previously published studies [6,8].
Patients underwent regular follow-up examinations
including ultrasound monitoring of the follicle growth
and daily measurements of LH, FSH, and progesterone
from the 9th day of their menstrual cycle. In case a patient
did not menstruate after LOD, bleeding was induced by
administration of progesterone after a maximum of 40
days after LOD. Patients were followed-up after LOD with
Table 1: Patient characteristics
Total number of patients 100
Age (years) 28.2 ± 4.7
Body mass index (kg/m2) 26.5 ± 4.4
Patients with primary infertility 69 (69.0%)
Patients with secondary infertility 31 (31.0%)Page 2 of 7
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phene citrate for a minimum of three months after LOD.
Laboratory analyses
Preoperative blood samples were taken from a peripheral
vein between seven days and two months before LOD. All
examined serum parameters were determined in the cen-
tral laboratory of the General Hospital of Vienna, Vienna,
Austria using commercially available assays. Radioimmu-
noassays were used to determine serum levels of LH
(Autodelfia; Wallac Oy, Turku, Finland), FSH (Enzymun
ES700; Böhringer Mannheim, Mannheim, Germany),
progesterone (Coat-ACoat RIA; DPC, Los Angeles, CA),
testosterone (Immunotech, Westbrook, ME, USA), and
androstenedione (Immunotech, Westbrook, ME, USA).
Surgical technique
Ninety-one patients were treated with bilateral LOD using
a monopolar electrocoagulation technique as previously
reported [11]. Thirty patients were operated with a
monopolar hook electrode (GK 375R, B. Braun Aesculap,
Maria Enzersdorf, Austria) and 5-10 incisions of 2-3 mm
length of the ovarian capsule.
The study was approved by the Ethics Committee of the
Medical University of Vienna, Vienna, Austria (Internal
Review Board number 388/2009). All procedures were
carried out in accord with the "Good Scientific Practice
Standards" set forth by the Medical University of Vienna,
which are based on the ethical standards of the Helsinki
Declaration of 1975.
Statistical analysis
Variables are described by frequencies and mean ± stand-
ard deviation (SD). Since there are 71 events in our study,
i.e. spontaneous ovulation after LOD, we tested 7 param-
eters by use of a univariate followed by a multivariate
regression model in order to identify factors predictive for
spontaneous ovulation after LOD. All parameters were
tested as continuous variables except for surgical tech-
nique which was tested as a categorial variable.
The optimal cut-off of the investigated parameters was cal-
culated automatically based on the receiver-operator char-
acteristics (ROC) curve by use of the MedCalc™ (version
10.4.8.0) software as the threshold value with the highest
specificity and sensitivity. The discriminatory ability of
the investigated parameters is described as the correlation
of specificity and sensitivity and is measured by the area
under the receiver-operating (AUC) curve. All values are
given with 95% confidence interval (95% CI).
Pre- and postoperative LH and androstenedione levels
were compared by means of paired t-tests. A p-value <
0.05 was considered statistically significant.
Results
One hundred of 121 patients (82.6%) underwent regular
follow-up examinations as described in the methods sec-
tion within three months after LOD. Twenty-one patients
were lost to follow-up and were excluded from the study.
Characteristics of the remaining 100 patients are shown in
Table 1. Thirty-two of 100 patients became spontaneously
pregnant within three months after LOD. Pregnancy was
confirmed by determination of β-HCG serum levels and
vaginal ultrasound.
Preoperative measurement of hormonal parameters was
done 32.9 ± 9.1 days before LOD. Table 2 shows the
details of preoperative hormone levels of all 100 study
patients. Spontaneous ovulation within three months
after LOD was found in 71/100 patients (71.0%). Patients
ovulated for the first time within 37.8 ± 10.4 days after
LOD. Differences in patient characteristics and hormonal
parameters between patients with and without spontane-
ous ovulation after LOD are listed in Table 3. We used a
univariate and a multivariate regression model in order to
identify independent predictors of spontaneous ovulation
after LOD. In the multivariate analysis, LH and androsten-
edione levels were significantly associated with spontane-
ous ovulation after LOD (p < 0.001 and p = 0.019,
respectively). Details are given in Table 4.
For LH the AUC of the ROC curve was 0.88 (95% CI: 0.80
- 0.94), for androstenedione the AUC of the ROC curve
was 0.65 (95% CI: 0.55 - 0.75). In order to maximize the
sum of positive and negative predictive values, a cut-off of
12.1 IU/l for LH and of 3.26 ng/ml for androstenedione
were evaluated. Sixty-three of 70 (90.0%) and 36/42
(85.7%) patients with elevated LH and androstenedione
levels, respectively, ovulated spontaneously after LOD.
Among patients with LH and androstenedione below the
cut-off, spontaneous ovulation was found in 8/30
(26.7%) and 35/58 cases (60.3%), respectively. When
both LH and androstenedione were analysed together, 0/
31 patients (0.0%) with both LH and androstenedione
exceeding the cut-off points and 16/19 patients (84.2%)
with LH and androstenedione below the cut-off point
remained anovulatory. Sensitivity, specificity, positive
predictive value (PPV), and negative predictive value
(NPV) to predict spontaneous ovulation are given in
Table 5.
Table 2: Preoperative measurement of hormonal parameters
Hormones
Luteinizing hormone (IU/l) 15.1 ± 6.0
Follicle stimulating hormone (IU/l) 6.2 ± 1.7
Testosterone (ng/ml) 0.8 ± 0.4
Androstendione (ng/ml) 3.2 ± 0.9Page 3 of 7
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patients (74.0%). Twenty-two of 71 patients (31.0%)
with spontaneous ovulation in contrast to 4/29 patients
without spontaneous ovulation (13.8%) were lost to fol-
low-up (p = 0.075). Of the 74 patients with follow-up,
three women became pregnant after in-vitro fertilization
within one year after LOD and thus they were excluded
from the pregnancy rate and life birth rate analyses.
Fourty-one women became spontaneously pregnant and
two women became pregnant after clomiphene citrate
stimulation within one year after LOD resulting in a one-
year pregnancy rate of 43/71 (60.6%). Of these, 36 preg-
nancies resulted in a life birth (36/71; 50.7%). Consider-
ing life-birth after spontaneous conception as a clinical
endpoint, 32/48 (66.7%) and 16/36 (44.4%) patients
with elevated LH and androstenedione levels, respec-
tively, gave birth to a child. Among patients with LH and
androstenedione below the cut-off, life birth was observed
in 4/23 (17.4.7%) and 20/35 women (57.1%), respec-
tively.
All 13 patients with both LH and androstenedione above
the respective cut-offs achieved a life birth, whereas only
33/58 (39.7%) women with LH or androstenedione
below the cut-offs gave birth to a child. Sensitivity, specif-
icity, PPV, and NPV of LH and androstenedione to predict
life birth are given in Table 5.
Table 6 gives an overview of pre- and postoperative LH
and androstenedione levels. Postoperative LH and
androstenedione levels were available in 82/100 patients
(82.0%). The first postoperative measurement of hormo-
nal parameters was done 30.1 ± 17.1 days after the opera-
tion. Statistically significant declines of both parameters
were found in all patient groups, except in those with LH
levels below the cut-off: LOD did not lead to a reduction
of androstenedione levels in these patients.
Discussion
In this retrospective study of 100 women with clomi-
phene citrate-resistant PCOS, preoperative LH and
androstenedione levels were found to be independent
predictors of spontaneous ovulation after LOD.
LH is known to stimulate ovarian theca cells to produce
androstenedione. Additionally, it is responsible for ovula-
tion and luteinization. Elevated levels of LH are character-
istic for women with PCOS [12]. In our study collective,
significantly higher preoperative LH levels were found in
responders to LOD compared to non-responders. This is
in accordance with a study published by Hayashi et al. [8]
demonstrating a good ovulation response in women with
clomiphene citrate-resistant PCOS when the preoperative
LH level was higher than 8.0 IU/l (sensitivity 73%, posi-
tive predictive value 92%). By setting the LH cut-off to
12.1 IU/l in our study, a sensitivity of 89% and a positive






Age (years) 26.2 ± 4.4 27.1 ± 4.2 n.s.a









Luteinizing hormone (IU/l) 17.3 ± 5.3 9.9 ± 4.1 <.001
Follicle stimulating hormone (IU/l) 6.4 ± 1.6 5.8 ± 1.9 n.s.a
Testosterone (ng/ml) 0.8 ± 0.4 0.7 ± 0.3 n.s.a
Androstendione (ng/ml) 3.4 ± 1.0 2.9 ± 0.7 .018
a n.s. = not significant
Table 4: Variables associated with induction of spontaneous ovulation
Univariate analysis Multivariate analysis
Variable Odds ratio 95% CIa P value Odds ratio 95% CIa P value
Age 0.96 [0.87; 1.05] .384
Body mass index 0.96 [0.87; 1.05] .373
Surgical technique 0.85 [0.33; 2.21] .737
Luteinizing hormone 1.51 [1.28; 1.78] <.001 1.58 [1.30; 1.92] <.001
Follicle stimulating hormone 1.27 [0.97; 1.66] .078
Testosterone 3.31 [0.73; 15.09] .122
Androstendione 2.18 [1.14; 4.14] .018 3.03 [1.20; 7.67] .019
aCI = confidence intervalPage 4 of 7
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ilar to that reported by Abdel et al. (12 IU/l) [6], whereas
Li et al. reported that 10 IU/l was an optimal cut-off for
the prediction of LOD success [7].
Our study adds androstenedione as an independent pre-
dictive parameter. PCOS patients who ovulated after LOD
showed significantly higher preoperative androstenedi-
one levels than patients who did not respond to LOD (3.4
± 1.0 vs. 2.9 ± 0.7 ng/ml, respectively; p = 0.02). This is
somewhat contradictory to a study published in 1985.
Aakvard and Gjonnaess reported that women ovulating
after electrocauterization of the ovarian capsule showed
lower androstenedione levels prior to surgery [13]. How-
ever, these patients had not been pretreated with met-
formin which might explain the difference between their
and our results: Metformin treatment is known to lead to
a reduction of testosterone but not androstenedione in
women with PCOS [14]. It has been demonstrated that
metformin reduces messenger RNA expression and activ-
ity of aromatase/CYP19, an enzyme specifically metabo-
lizing androstenedione [15].
By combining both parameters, i.e. LH and androstenedi-
one, we were able to optimize the accuracy for predicting
ovulation after LOD, reaching both a specifity and a posi-
tive predictive value of 100%.
Complete one-year follow-up was available for 74% of
our patients. Notably, 31% of women with spontaneous
ovulation in contrast to 14% of women, who remained
anovulatory, were lost to follow-up. Although this differ-
ence failed to reach significance (p = 0.07), this finding
may be considered a hint that preferentially patients in
whom LOD had led to a therapeutic success have not been
followed-up, a fact that might has introduced bias.
Another possible source of bias is surgical technique. It is
of note that in 30 patients (30%) LOD was performed by
use of a monopolar hook electrode, a technique that has
not been published so far. However, univariable regres-
Table 5: Accuracy of LH and androstendione cut-off points to predict spontaneous ovulation and life birth
Spontaneous ovulation (n = 100) Life birth (n = 71)
LH >12.1 IU/l Androstenedione 
>3.26 mg/dl




LH >12.1 IU/l Androstenedione 
>3.26
LH >12.1 IU/l and 
androstenedione 
>3.26 mg/dl
Sensitivity (%) 88.7 (95% CI 
79.0-95.0)a
50.7 (95% CI 
38.6-62.8)a




44.4 (95% CI: 
27.9-61.9)
36.1 (95% CI: 
20.2-52.5)
Specifity (%) 75.9 (95% CI 
56.5-89.7)a
79.3 (95% CI 
60.3-92.0)a
100.0 (95% CI: 
85.0-100.0)a
54.3 (95% CI: 
36.6-71.2)
42.9 (95% CI: 
26.3-60.6)





90.0 (95% CI 
80.5-95.8)a
85.7 (95% CI 
71.5-94.6)a




44.4 (95% CI: 
27.9-61.9)





73.3 (95% CI 
54.1-87.7)a
39.7 (95% CI 
27.0-53.4)a
42.0 (95% CI: 
29.8-53.8)a
82.6 (95% CI: 
61.2-95.0)
42.9 (95% CI: 
26.3-60.6)
60.3 (95% CI: 
45.8-71.9)
aCI = confidence interval
Table 6: Pre- and postoperative LH and androstenedione levels
LH Androstenedione
Preoperative Postoperative P Preoperative Postoperative P
Total study 
population
15.1 ± 6.0 6.4 ± 4.0 < 0.001 3.2 ± 0.9 2.2 ± 1.6 < 0.001
LH ≤12.1 IU/l 8.4 ± 2.2 6.1 ± 3.3 0.004 3.1 ± 1.0 3.0 ± 2.7 0.708
>12.1 IU/l 18.0 ± 4.6 6.6 ± 4.3 < 0.001 3.2 ± 0.9 1.9 ± 0.7 < 0.001
Androstenedione ≤3.26 mg/dl 14.5 ± 5.4 6.5 ± 4.3 < 0.001 2.6 ± 0.5 1.8 ± 0.6 < 0.001
>3.26 mg/dl 16.0 ± 6.7 6.4 ± 3.5 < 0.001 6.4 ± 0.9 2.7 ± 2.3 < 0.001
LH and 
androstenedione
LH ≤ 12.1 IU/l or 
androstenedione ≤ 3.26 mg/dl
13,7 ± 5,4 6,6 ± 4,0 < 0.001 2.8 ± 0.8 2.3 ± 2.0 0.029
LH >12.1 IU/l and 
androstenedione >3.26 mg/dl
18,3 ± 5,9 6,1 ± 4,0 < 0.001 3.9 ± 0.8 2.0 ± 0.6 < 0.001Page 5 of 7
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not influence the response to LOD (p = 0.7).
In our data set, LOD led to a one-year pregnancy rate of
61% which is comparable to the majority of publications
reporting pregnancy rates of 50-60% after LOD [16]. The
resulting life birth rate was 51% in our study. Due to the
fact that 29% of patients were lost to follow-up, we chose
the pregnancy and life birth rates as secondary objectives
only. The LH and androstendione cut-off points were
evaluated to predict spontaneous ovulation. Nonetheless,
the LH cut-off point of 12.1 IU/l also seems to be a valua-
ble tool for the prediction of life birth after LOD with a
sensitivity of nearly 90% and a negative predictive value of
about 82%, whereas we consider the use of the androsten-
edione cut-off of 3.26 mg/dl inaccurate, since its sensitiv-
ity, specifity, negative and positive predictive values for
life birth were about 43% only. In contrast, the combina-
tion of both parameters led to a specificity and a positive
predictive value of 100% to predict life birth.
LOD puts the patient at risk for ovarian damage. A reduc-
tion in the ovarian reserve and, in the worst case, ovarian
failure have been reported to be rare but possible compli-
cations of surgery for PCOS [17,18]. In addition, adhesion
formation with subsequent impairment of fertility may
occur after LOD [18]. With these serious complications in
mind, we consider preoperative LH and androstenedione
levels potentially helpful tools which allow for the predic-
tion of the therapeutic outcome of LOD. Accordingly, LH
and androstendione levels might be helpful to detect
those patients who will most likely benefit from LOD. In
this respect, putting patients who might not benefit from
LOD at risk of ovarian failure and surgical complications
could be avoided.
None of the other tested parameters showed a significant
association with the response to LOD. Neither age, nor
BMI levels were different comparing ovulating and non-
ovulating patients. In previous studies, it has been
reported that LOD outcome was better in younger
patients and in those with a normal body mass index
[7,10], a finding which we cannot confirm. As a possible
explanation, it might be argued that this difference was
due to the fact that all of our patients had been pretreated
with metformin.
LOD markedly decreased postoperative LH and andros-
tenedione levels demonstrating its effectiveness. This was
especially true for patients with androstenedione levels
>3.26 ng/ml and for patients with both LH and andros-
tenedione exceeding the cut-off.
Our data should only be applied to clomiphene citrate-
resistant PCOS women who had been pretreated with
metformin. Whether higher androstenedione levels might
predict spontaneous ovulation after LOD remains open.
We consider this a study limitation.
Conclusions
We consider LH and androstenedione levels simple and
valuable tools in predicting the therapeutic success of
LOD in patients with clomiphene citrate-resistant PCOS
pretreated with metformin. We suggest to preferentially
performing LOD in patients with high LH and androsten-
edione levels.
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